期刊文献+

表阿霉素联合紫杉醇新辅助化疗治疗局部晚期乳腺癌疗效分析 被引量:5

下载PDF
导出
摘要 目的观察表阿霉素联合紫杉醇新辅助化疗在局部晚期乳腺癌中应用的临床效果。方法根据患者意愿将局部晚期乳腺癌68例患者分为观察组与对照组各34例。观察组患者采用表阿霉素联合紫杉醇辅助化疗,对照组患者采用表柔比星、环磷酰胺联合氟尿嘧啶联合治疗,治疗3个疗程后对2组患者原发病临床治疗效果及毒性反应进行观察。结果观察组总有效率为73.5%高于对照组的52.9%(P<0.05);观察组患者毒性反应发生率明显小于对照组(P<0.05)。结论采用表阿霉素联合紫杉醇辅助治疗局部晚期乳腺癌临床效果显著,毒性反应均可耐受,可作为局部晚期乳腺癌治疗的有效治疗手段推广使用。
作者 刘一范
出处 《临床合理用药杂志》 2014年第19期60-61,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献3

二级参考文献24

  • 1[1]Heller W,Mazhar D,Ward R.et al.Neoadjuvant 5-fluorouracll,epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.Oncol Rep,2007,17:253-259.
  • 2[2]Sarid D,Ron I G,Sperber F,et al.Neoadjuvant treatment with paclltaxd and epirubicin in invasive breast cancer:a phase Ⅱstudy.Clin Drug Investig,2006,26:691-701.
  • 3[3]Fernández Morales L A,SeguíM A,Andreu X,et al.Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor,progesterone receptor,and HER-2 status.Clin Breast Cancer,2007,7:559-564.
  • 4[4]Tiezzi D G,Andrade J M,Ribeiro silva A,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicincombination.BMC Cancer,2007,7:36.
  • 5[5]Learn P A,Yeh I T,McNutt M,et al.HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.Cancer,2005,103:2252-2260.[6] Fernández Sánchez M,Gamboa Dominguez A,Uribe N,et al.Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanccd breast cancer.Med Oncol,2006,23:171-183.
  • 6[7]Zhang B,Zhang Q,Zhan L,et al.Assessment of neoadjuvant chemotherapy in breast cancer patients.Zhonghua Zhong Liu Za Zhi,2006.28:867-870.
  • 7[8]Tacca O.Penault Llorca F,Abrial C,et al.Changes in and prognostic value of hormone receptor status in a aeries of operable breast cancer patients treated with neoadjuvant chemotherapy.Oncologlst,2007,12:636-643.
  • 8[9]Varga z,Caduff R,Pestalozzi B,et al.Stability of the HER-2 gene after primary chemotherapy in advanced breast cancer.Virchows Arch,2005,446:136-141.
  • 9[10]Arens N,Bleyl U,Hildenbrand R,et al.HER-2/neu,p53,Ki67,and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.Virchows Arch,2005,446:489-496.
  • 10[11]Tfayli A,Holter J,Bova A,et al.Activity of combination chemotherapy,docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.Anticancer Res,2006,26:4911-4916.

共引文献31

同被引文献36

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部